Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

FDA Approves Bavencio Plus Inlyta Combination for Patients with Advanced Renal Cell Carcinoma

EMD Serono and Pfizer announced that the U.S. FDA approved Bavencio (avelumab) in combination with Inlyta (axitinib) for the first-line treatment of patients with advanced renal cell carcinoma.

Read More »

London HIV patient becomes world’s second AIDS cure hope

An HIV-positive man in Britain became the second known adult worldwide to be cleared of the AIDS virus after he received a bone marrow transplant from an HIV resistant donor, his doctors said.

Read More »

Top 10 Pipelines To Watch: 2019 Annual Report

The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.

Read More »

Sen. Sanders, Rep. Cummings to introduce bill to lower U.S. drug prices

U.S. Senator Bernie Sanders and Representative Elijah Cummings plan to introduce legislation aimed at lowering the cost of prescription drugs for U.S. consumers.

Read More »

Survey Indicates Healthcare Professionals Have a Dim View of Post-Brexit Britain

A new report indicates that the so-called “Brexit” will have a negative impact on healthcare in the United Kingdom.

Read More »

WHO uncovers big national variations in antibiotics consumption

Antibiotics are used far more in some countries than in others, a survey by the World Health Organization showed, suggesting that urgent action was needed to slash unnecessary consumption of the medicines.

Read More »

UK clinical trials fall as Brexit clouds drug approval process

The number of new clinical trials started in Britain during 2017 was 25 percent lower than the average for 2009-2016, as anxiety about Brexit’s impact on future medicines regulation made companies hesitate about running studies in the country.

Read More »

Novo Nordisk to cut 250 jobs in the United States

Denmark’s Novo Nordisk will cut around 250 jobs in the United States, but the drugmaker will also hire an as-yet undetermined number of staff to new positions.

Read More »

Novo Nordisk lays off 400 staff in R&D unit

Novo Nordisk said the world’s top maker of diabetes drugs will lay off 400 staff in Denmark and China as part of a broader restructuring of the company’s research and development organization.

Read More »

Half of Europe’s clinical trials fail to report results

Almost half of all European-registered clinical trials have breached EU rules by failing to report results, according to a published analysis.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom